Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theophylline Treatment for Pseudohypoparathyroidism
NCT03029429Phase 2Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of theophylline in pseudohypoparathyroidism (PHP), sponsored by Vanderbilt University Medical Center. Started Sep 2018; status: active, not recruiting.
02
Drugs
theophylline
03
Conditions
pseudohypoparathyroidism (PHP)
Beyond the preview
Go deeper on NCT03029429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029429.